Abstract
Sildenafil, usually a well-tolerated drug traditionally used for erectile dysfunction (ED), was recently approved for pulmonary arterial hypertension. In the literature, there are few cases of hemoptysis following sildenafil use for ED; however, to our knowledge, we are reporting the first case of hemoptysis following sildenafil use for pulmonary hypertension. We are documenting a case of a 90-year-old male patient who was admitted to the intensive care unit with hemoptysis and respiratory failure two weeks after he was started on sildenafil.
MeSH terms
-
Aged, 80 and over
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Aspirin / adverse effects
-
Aspirin / therapeutic use
-
Drug Therapy, Combination
-
Hemoptysis / chemically induced*
-
Humans
-
Hypertension, Pulmonary / drug therapy*
-
Intensive Care Units
-
Male
-
Patient Admission
-
Piperazines / adverse effects*
-
Piperazines / therapeutic use
-
Purines / adverse effects
-
Purines / therapeutic use
-
Respiratory Insufficiency / chemically induced*
-
Sildenafil Citrate
-
Sulfones / adverse effects*
-
Sulfones / therapeutic use
-
Vasodilator Agents / adverse effects*
-
Vasodilator Agents / therapeutic use
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Piperazines
-
Purines
-
Sulfones
-
Vasodilator Agents
-
Sildenafil Citrate
-
Aspirin